Orexo: Zubsolv Rx Data week 11

Research Update

2015-03-20

15:22

Latest Wolter Kluwer data came in on the positive side and Zubsolv tablets market share showed a w/w increase of 0.19 percentage points to 6.27%. The four week rolling average increased to 6.12%, up from 6.04% previous week. TRx recorded new record levels of 10,801 equivalent to a market share of 5.69% and a four week rolling average of 5.61%. Zubsolv seems to be winning market share from generic products. The overall buprenorphine/naloxone unit sales y/y rose by 13.7%.

KP

Klas Palin

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.